Evaluation of the Efficacy and Safety of Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS) in the Therapeutic Algorithm of Patients with Liver Cirrhosis.
Launched by HOSPITAL UNIVERSITARIO VIRGEN MACARENA · Oct 28, 2024
Trial Information
Current as of July 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new method for measuring portal pressure in patients with liver cirrhosis, a serious condition where the liver is severely damaged. The study aims to see if using a technique called Endoscopic Ultrasound (EUS) to measure pressure is safe and effective. This method could help doctors understand how well patients might respond to a specific medication called non-selective beta-blockers (NSBBs), which are used to prevent complications related to liver cirrhosis. By determining which patients would benefit from this treatment, the trial could improve care for those with advanced liver disease.
To participate in this trial, individuals must be between the ages of 65 and 74 and have advanced liver disease that requires prevention treatment. However, some people will not be eligible, including those under 18, pregnant women, or those with certain health issues. Participants can expect to undergo EUS for the pressure measurement, and the study will help doctors learn more about managing liver cirrhosis effectively. It's important to note that the trial has not started recruiting participants yet, so interested individuals will need to wait until it begins.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with advanced liver disease with an indication for primary prophylaxis with NSBBs
- Exclusion Criteria:
- • - Age \< 18 years. 2. Advanced stage hepatocellular carcinoma not eligible for curative treatment. 3. Pregnancy. 4. Esophageal stenosis. 5. INR \> 1.5. 6. Platelets \< 50,000 µL. 7. Ascites. 8. Patients with any contraindication for performing an upper gastrointestinal endoscopy.
- • 9. Patients with contraindication to NSBB treatment. 10. Refusal to sign the informed consent form to participate in the study
About Hospital Universitario Virgen Macarena
Hospital Universitario Virgen Macarena is a leading academic medical center located in Seville, Spain, dedicated to advancing healthcare through innovative clinical research and patient care. As a prominent sponsor of clinical trials, the hospital leverages its multidisciplinary expertise and state-of-the-art facilities to facilitate groundbreaking studies that aim to improve treatment outcomes and enhance medical knowledge. With a commitment to ethical standards and patient welfare, Hospital Universitario Virgen Macarena collaborates with a network of healthcare professionals and researchers to contribute significantly to the field of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sevilla, , Spain
Patients applied
Trial Officials
RAFAELR R ROMERO CASTRO, DOCTOR
Study Director
SAS
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported